Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	97381
Country	Egypt

Received	2024-05-29 22:06
Peer-Review Started	2024-05-29 22:06
To Make the First Decision
Return for Revision	2024-08-15 19:46
Revised	2024-08-28 07:35
Second Decision	2024-09-23 02:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-09-23 10:43
Articles in Press	2024-09-23 10:43
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-09-30 10:54
Publish the Manuscript Online	2024-10-25 03:02

ISSN	2150-5349 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis
Manuscript Source	Invited Manuscript
All Author List	Mohamed Abdel-Samiee, Essam Salah Ibrahim, Mohamed Kohla, Eman Abdelsameea and Mohsen Salama
Funding Agency and Grant Number
Corresponding Author	Eman Abdelsameea, MD, Full Professor, Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebin El-Kom 32511, Egypt. eabdelsameea@liver-eg.org
Key Words	Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Myofibroblasts; Fibrosis; Antifibrotic pharmacotherapy; Nonalcoholic fatty liver disease treatment strategies; Emerging treatments for nonalcoholic steatohepatitis
Core Tip	Non-alcoholic fatty liver disease (NAFLD) global incidence is escalating significantly. NAFLD covers a range of liver conditions, from simple steatosis to the more severe form known as non-alcoholic steatohepatitis, which involves chronic liver inflammation and the transformation of hepatic stellate cells into myofibroblasts that generate excess extracellular matrix, leading to fibrosis. Hepatocyte ballooning is a key catalyst for fibrosis progression.
Publish Date	2024-10-25 03:02
Citation	<p>Abdel-Samiee M, Ibrahim ES, Kohla M, Abdelsameea E, Salama M. Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis. <i>World J Gastrointest Pharmacol Ther</i> 2024; 15(6): 97381</p>
URL	https://www.wjgnet.com/2150-5349/full/v15/i6/97381.htm
DOI	https://dx.doi.org/10.4292/wjgpt.v15.i6.97381

Full Article (PDF)	WJGPT-15-97381-with-cover.pdf
Manuscript File	97381_Auto_Edited_035506.docx
Answering Reviewers	97381-answering-reviewers.pdf
Audio Core Tip	97381-audio.mp3
Conflict-of-Interest Disclosure Form	97381-conflict-of-interest-statement.pdf
Copyright License Agreement	97381-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	97381-non-native-speakers.pdf
Peer-review Report	97381-peer-reviews.pdf
Scientific Editor Work List	97381-scientific-editor-work-list.pdf
Scientific Editor Work List	97381-scientific-editor-work-list.png
CrossCheck Report	97381-crosscheck-report.pdf
CrossCheck Report	97381-crosscheck-report.png